Antiandrogenic activity of anthranilic acid ester derivatives as novel lead structures to inhibit prostate cancer cell proliferation

Chemical Biology and Drug Design

Volumn 77, Issue 6, 2011, Pages 450-459

  Roell, Daniela ^a   Rösler, Thomas W ^b   Degen, Stephanie ^a   Matusch, Rudolf ^b   Baniahmad, Aria ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Anthranilic acid; AR antagonism; Ester derivative; Methyl anthranilate; Prostate cancer; Sabal serrulata; Serenoa repens

Indexed keywords

ANDROGEN RECEPTOR; ANTHRANILIC ACID DERIVATIVE; ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN; SABAL EXTRACT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG SYNTHESIS; HORMONE INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER;

ANDROGEN ANTAGONISTS; ANTHRANILIC ACIDS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MALE; MUTATION; PLANT EXTRACTS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SERENOA;

SERENOA REPENS;

EID: 79955958923     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01116.x     Document Type: Article

References (34)

1. Edwards B.K., Ward E., Kohler B.A., Eheman C., Zauber A.G., Anderson R.N., Jemal A., Schymura M.J., Lansdorp-Vogelaar I., Seeff L.C., van Ballegooijen M., Goede S.L., Ries L.A.G. (2010) Annual Report to the Nation on the Status of Cancer, 1975-2006, Featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer;116:544-573.
2. Evans R.M. (1988) The steroid and thyroid hormone receptor superfamily. Science;240:889-895.
3. Tenbaum S., Baniahmad A. (1997) Nuclear receptors: structure, function and involvement in disease. Int J Biochem Cell Biol;29:1325-1341.
4. Riegman P.H., Vlietstra R.J., van der Korput J.A., Brinkmann A.O., Trapman J. (1991) The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol;5:1921-1930.
5. Taplin M.E., Bubley G.J., Ko Y.J., Small E.J., Upton M., Rajeshkumar B., Balk S.P. (1999) Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res;59:2511-2515.
6. Bohl C.E., Wu Z., Miller D.D., Bell C.E., Dalton J.T. (2007) Crystal structure of the T877A human androgen receptor ligand-binding domain complex to cyproterone acetate provides insight for ligand-induced conformational changes and Structure based Drug-design. J Biol Chem;282:13648-13655.
7. Murray M.T., Pizzorno J. (1998) Encyclopedia of Natural Medicine, 2nd edn. Roseville, USA: Prima Publishing.
8. Kraemer H. (1910) A Text-Book of Botany and Pharmacognosy, 4th edn. Philadelphia, USA: J.B. Lippincott, 578 p.
9. Hiermann A. (1989) Über die Inhaltsstoffe von Sabalfrüchten und deren Prüfung auf entzündungshemmende Wirkung. Arch Pharm;322:111-114.
10. Vacherot F., Azzouz M., Gil-Diez-De-Medina S., Colombel M., De La Taille A., Belda M.-A.L., Abbou C.C., Raynaund J.-P., Chopin D.K. (2000) Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, PermixonT) in benign prostatic hyperplasia. Prostate;45:258-266.
11. Schleich S., Papaioannou M., Baniahmad A., Matusch R. (2006) Extracts from Pygeum africanum and other ethnobotanical species with antiandrogenic activity. Planta Med;72:807-813.
12. Raynaud J.-P., Cousse H., Martin P.-M. (2002) Inhibition of type 1 and type 2 5α-reductase activity by free fatty acids, active ingredients of Permixon®. J Steroid Biochem Mol Biol;82:233-239.
13. Papaioannou M., Schleich S., Roell D., Schubert U., Tanner T., Claessens F., Matusch R., Baniahmad A. (2010) NBBS isolated from Pygeum africanum bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth. Invest New Drugs;28:729-743.
14. Moehren U., Papaioannou M., Reeb C., Grasselli A., Nanni S., Asim M., Roell D., Prade I., Farsetti A., Baniahmad A. (2008) Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development. FASEB J;22:1258-1267.
15. Dotzlaw H., Moehren U., Mink S., Cato A., Iniguez Lluhi J.A., Baniahmad A. (2002) The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol Endocrinol;16:661-673.
16. Schulz M., Eggert M., Baniahmad A., Dostert A., Heinzel T., Renkawitz R. (2002) RU486-induced glucocorticoid receptor agonism is controlled by the receptor N-terminus and by corepressor binding. J Biol Chem;277:26238-26243.
17. Protopopov A.I., Li J., Winberg G., Gizatullin R.Z., Kashuba V.I., Klein G., Zabarovsky E.R. (2002) Human cell lines engineered for tetracycline-regulated expression of tumor suppressor candidate genes from a frequently affected chromosomal region, 3p21. J Gene Med;4:397-406.
18. Papaioannou M., Schleich S., Prade I., Degen S., Roell D., Schubert U., Tanner T., Claessens F., Matusch R., Baniahmad A. (2009) The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growth. J Cell Mol Med;13:2210-2223.
19. Gast A., Schneikert J., Cato A. (1998) N-terminal sequences of the human androgen receptor in DNA binding and transrepressing functions. J Steroid Biochem Mol Biol;65:117-123.
20. Habib F.K., Ross M., Ho C.K., Lyons V., Chapman K. (2005) Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression. Int J Cancer;114:190-194.
21. Hänsel R., Schöpflin G., Rimpler H. (1966) Notiz über das Vorkommen von Anthranilsäure in Sabalfrüchten (Serenoa repens). Planta Med;14:261-265.
22. Gebauer H. (2006) Use of angelic acid esters as an antiphlogistic active ingredient and antiphlogistic Preparations. Patent De 102006012107.
23. Zhu W., Smith A., Young C.Y. (1999) A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells. Endocrinology;140:5451-5454.
24. Staiger R.P., Miller E.B. (1959) Isatoic anhydride. IV. Reactions with various nucleophiles. J Org Chem;24:1214-1219.
25. Luo S., Martel C., LeBlanc G., Candas B., Singh S.M., Labrie C., Simard J., Bélanger A., Labrie F. (1996) Relative potencies of flutamide and casodex: preclinical studies. Endocr-relat. Cancer;3:229-241.
26. 3H]cortisol binding to plasma proteins. J Steroid Biochem;33:251-255.
27. Moehren U., Papaioannou M., Reeb C., Hong W., Baniahmad A. (2007) Alien interacts with the human androgen receptor and inhibits prostate cancer cell growth. Mol Endocrinol;21:1039-1048.
28. Eisold M., Asim M., Eskelinen H., Linke T., Baniahmad A. (2009) Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens. Mol Endocrinol;42:429-435.
29. Kang Z., Jänne O.A., Palvimo J. (2004) Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol;8:2633-2648.
30. Fahelbum I.M.S., James S.P. (1979) Absorption, distribution and metabolism of propyl anthranilate. Toxicology;12:75-87.
31. Bélanger A., Giasson M., Couture J., Dupont A., Cusan L., Labrie F. (1988) Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide. Prostate;12:79-84.
32. Jenner P.M., Hagan E.C., Taylor J.M., Cook E.L., Fitzhugh O.G. (1964) Food flavourings and compounds of related structure I. Acute oral toxicity. Food Cosmet Toxicol;2:327-343.
33. Charconnet-Harding F., Dalgliesh C.E., Neuberger A. (1953) The relation between riboflavin and tryptophan metabolism, studied in the rat. Biochem J;53:513-521.
34. Hagan E.C., Hansen W.H., Fitzhugh O.G., Jenner P.M., Jones W.I., Taylor M.J., Long E.L., Nelson A.A., Brouwer J.B. (1967) Food flavourings and compounds of related structure II. Subacute and chronic toxicity. Food Cosmet Toxicol;5:141-157.